A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2017
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 18 Aug 2016 Status changed from not yet recruiting to recruiting.
- 30 May 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jun 2016.
- 18 Dec 2015 New trial record